APELLIS PHARMACT.DL-0001
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more
APELLIS PHARMACT.DL-0001 (1JK) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, APELLIS PHARMACT.DL-0001 (1JK) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
APELLIS PHARMACT.DL-0001 - Net Assets Trend (None–None)
This chart illustrates how APELLIS PHARMACT.DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for APELLIS PHARMACT.DL-0001 (None–None)
The table below shows the annual net assets of APELLIS PHARMACT.DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to APELLIS PHARMACT.DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
APELLIS PHARMACT.DL-0001 Competitors by Market Cap
The table below lists competitors of APELLIS PHARMACT.DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Shiyuan Electronic Technology Co Ltd
SHE:002841
|
$1.44 Billion |
|
89bio Inc
NASDAQ:ETNB
|
$1.44 Billion |
|
Jungheinrich AG Pfd.
LSE:0EXP
|
$1.44 Billion |
|
ELVALHALCOR NA EO 039
F:HC6A
|
$1.44 Billion |
|
JC Decaux SA
PA:DEC
|
$1.44 Billion |
|
Lions Gate Entertainment Corp
NYSE:LGF-A
|
$1.44 Billion |
|
Harmony Biosciences Holdings
NASDAQ:HRMY
|
$1.44 Billion |
|
BVHMY
PINK:BVHMY
|
$1.44 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in APELLIS PHARMACT.DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares APELLIS PHARMACT.DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently APELLIS PHARMACT.DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares APELLIS PHARMACT.DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| APELLIS PHARMACT.DL-0001 (1JK) | €- | N/A | N/A | $1.44 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |